Cadralazine

This classification denotes an antihypertensive agent with the molecular formula C12H21N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8T96I3U713, chemically known as hydrazinecarboxylic acid, 2-(6-(ethyl(2-hydroxypropyl)amino)-3-pyridazinyl)-, ethyl ester but generally known as cadralazine, which bears US NIH Compound Identifier 2515. European Medicines Agency schedules Cadralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06042MIG. The term CADRALAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules cadralazine in its Anatomical Therapeutic Chemical (ATC) Classification. CADRALAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cadralazine under HS 29339990 and SITC 51577. As of Q4 2014, CADRALAZINE remains the US FDA Preferred Term for this commodity. Cadralazine bears US NLM identifiers UMLS ID C0054422 and NCI Concept Code C81527. SMILES: OC(CN(CC)c1nnc(NNC(=O)OCC)cc1)C.